Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Reduction of Oncogene Activity Causes Cancer Cells to Revert to Normal

By Biotechdaily staff writers
Posted on 09 Jul 2008
Cancer researchers working with a mouse model have found that by reducing the activity of the Myc oncogene, they could reverse the uncontrolled growth of cancer cells and return them to a normal, healthy state.

All normal cells require Myc activity. More...
However, Myc overexpression causes cells to grow too large and multiply uncontrollably. Previous studies have shown that eliminating Myc caused the death of tumor cells but had the same effect on normal tissues.

In the current study investigators at Stanford University (Palo Alto, CA, USA) worked with mice that had been genetically engineered to develop Myc-driven tumors in response to a chemical in their drinking water. After triggering tumor development at high levels of Myc activity, they gradually reduced the level of Myc. During this process they monitored both the genomic - oligonucleotide microarray analysis and quantitative PCR were used to identify changes in expression in 3,921 genes – and proteomic status of the cells. In the latter case, two-dimensional protein analysis followed by mass spectrometry, phospho-flow fluorescence-activated cell sorting, and antibody arrays were employed.

Results published in the July 1, 2008, issue of the journal Cancer Research revealed that as the Myc concentration reached the critical level where cancer cells began to revert to normal 2,348 genes were down-regulated while 1,573 were up-regulated, and proteins involved in mRNA translation decreased. In short, at the MYC threshold level, there was a loss of the oncogene's ability to maintain tumorigenesis, with associated shifts in gene and protein expression that reestablished cell cycle checkpoints, halted protein translation, and promoted apoptosis.

"In the past, scientists have shown that cancer signals such as Myc are like light switches,” said senior author Dr. Dean Felsher, associate professor of oncology and pathology at Stanford University. "Now we know that, in some cases, you do not need to turn the light completely off. We were able to experimentally prove that we can turn Myc off a little bit, or for a little time, and that is enough to have a profound effect on cancer.”


Related Links:
Stanford University

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.